1H-Indole-2-carboxylicacid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1H-Indole-2-carboxylicacid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-
• 英文别名: 1-[2-[(1-carboxy-3-phenylpropyl)amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
• 化学式: C₂₂H₃₀N₂O₅
• 分子量: 402.5
• InChiKey: AHYHTSYNOHNUSH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0037231A2

  公开（公告）日：1981-10-07

  Octahydro-1-(w-mercaptoalkanoyl)-1H-indole-2-carboxylic acid compounds having the formula wherein R is hydrogen or lower alkyl; R1 is hydrogen, lower 0 alkyl, or benzyl; R2 is hydrogen or R3-C- where R3 is lower alkyl, heteroaryl containing 4 to 9 carbon atoms and one or two nitrogen, oxygen or sulfur atoms; phenyl, substituted phenyl having 1 or 2 substituents selected from the group consisting of fluorine, chlorine, bromine, lower alkyl or alkoxy; and n is 0 or 1; wherein lower alkyl and lower alkoxy include straight or branched groups containing 1 to 4 carbon atoms, and pharmaceutically acceptable salts of the compounds when R is hydrogen and when R3 is heteroaryl containing 1 or 2 nitrogen atoms, are disclosed. Also disclosed are substituted acyl compounds of octahydro-lH-indole-2-carboxylic acid having the formula wherein R4 is hydrogen or lower alkyl; R5 is hydrogen, lower alkyl or benzyl; R6 is hydrogen or lower alkyl; Ar is phenyl or phenyl substituted with 1 or 2 substituents selected from the group consisting of fluorine, chlorine, bromine, lower alkyl, lower alkoxy, hydroxy or amino; and m is 0 to 3; wherein lower alkyl and lower alkoxy contain 1 to 4 straight or branched carbon atoms; and the pharmaceutically acceptable salts thereof. The compounds and the salts are useful for treating hypertension.

  八氢-1-(w-巯基烷酰基)-1H-吲哚-2-羧酸化合物，其式为 其中 R 是氢或低级烷基；R1 是氢、低级 0 烷基或苄基；R2 是氢或 R3-C-，其中 R3 是低级烷基、含 4 至 9 个碳原子和 1 或 2 个氮、氧或硫原子的杂芳基；苯基、具有 1 或 2 个取代基的取代苯基，取代基选自由氟、氯、溴、低级烷基或烷氧基组成的组；和 n 为 0 或 1；其中低级烷基和低级烷氧基包括含有 1 至 4 个碳原子的直链或支链基团，当 R 为氢和 R3 为含有 1 或 2 个氮原子的杂芳基时，公开了这些化合物的药学上可接受的盐。还公开了八氢-lH-吲哚-2-羧酸的取代酰基化合物，其式为 其中 R4 是氢或低级烷基；R5 是氢、低级烷基或苄基；R6 是氢或低级烷基；Ar 是苯基或被 1 或 2 个选自氟、氯、溴、低级烷基、低级烷氧基、羟基或氨基的取代基取代的苯基；m 是 0 至 3；其中低级烷基和低级烷氧基含有 1 至 4 个直链或支链碳原子；及其药学上可接受的盐。这些化合物及其盐类可用于治疗高血压。
• Neurogenesis by modulating angiotensin
  申请人：Braincells, Inc.

  公开号：EP2377531A2

  公开（公告）日：2011-10-19

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.

  本发明描述了通过刺激或增加神经发生来治疗中枢和外周神经系统疾病和病症的方法。本发明包括基于调节血管紧张素活性以刺激或激活新神经细胞形成的组合物和方法。
• NEUROGENESIS BY MODULATING ANGIOTENSIN
  申请人：Braincells, Inc.

  公开号：EP2021000A2

  公开（公告）日：2009-02-11
• Compositions and methods for treating contracture
  申请人：Avelar Rui

  公开号：US20050186261A1

  公开（公告）日：2005-08-25

  A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compositions, devices, and kits for use in treating contracture are also described.
• Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
  申请人：Gallop A. Mark

  公开号：US20070015716A1

  公开（公告）日：2007-01-18

  Disclosed are methods for providing enhanced systemic blood concentrations of orally delivered drugs that are incompletely translocated across the intestinal wall of an animal. Also disclosed are methods for the sustained release of drugs, whether poorly or readily bioavailable via oral delivery to animals. Still further, disclosed are compounds and pharmaceutical compositions that are used in such methods.